{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.3","upperLimit":"49.6","value":"38.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost","id":"OG000","title":"Cohort B - No Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All eligible patients on Cohort B who started study treatment. (See limitations and caveats, Cohort A is not included.)","reportingStatus":"POSTED","timeFrame":"From start of treatment to last follow-up. Analysis can occur at or after time of primary outcome measure analysis.","title":"Percentage of Patients With Other CTCAE, v.3.0 Grade 3-5 Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of patients"}